Hims & Hers Health, Inc. (NYSE:HIMS) Director Christopher D. Payne Acquires 110,000 Shares

Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report) Director Christopher D. Payne purchased 110,000 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, May 22nd. The stock was purchased at an average price of $17.74 per share, with a total value of $1,951,763.00. Following the completion of the purchase, the director now directly owns 110,000 shares in the company, valued at $1,951,763. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Hims & Hers Health Trading Up 4.0 %

HIMS opened at $21.62 on Tuesday. The company’s 50 day moving average is $15.10 and its 200-day moving average is $12.16. The company has a market cap of $4.64 billion, a P/E ratio of -2,161.50 and a beta of 1.08. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $22.10.

Hims & Hers Health (NYSE:HIMSGet Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $278.20 million during the quarter, compared to analysts’ expectations of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. Hims & Hers Health’s revenue was up 45.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.05) EPS. On average, equities analysts forecast that Hims & Hers Health, Inc. will post 0.18 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Bank of America upped their price target on shares of Hims & Hers Health from $17.25 to $22.00 and gave the company a “buy” rating in a research note on Monday, June 3rd. SVB Leerink started coverage on shares of Hims & Hers Health in a report on Monday, February 26th. They set a “market perform” rating and a $10.00 target price on the stock. Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a research note on Tuesday, May 7th. Jefferies Financial Group restated a “hold” rating and set a $15.00 price objective (down previously from $17.00) on shares of Hims & Hers Health in a research note on Tuesday, April 16th. Finally, Truist Financial upped their target price on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.14.

View Our Latest Stock Analysis on HIMS

Institutional Trading of Hims & Hers Health

Several hedge funds and other institutional investors have recently made changes to their positions in HIMS. FNY Investment Advisers LLC bought a new position in Hims & Hers Health in the 4th quarter valued at approximately $48,000. Belpointe Asset Management LLC acquired a new position in shares of Hims & Hers Health during the third quarter worth $76,000. EMC Capital Management grew its stake in shares of Hims & Hers Health by 80.0% in the third quarter. EMC Capital Management now owns 12,000 shares of the company’s stock worth $79,000 after purchasing an additional 5,332 shares during the last quarter. Certuity LLC bought a new stake in shares of Hims & Hers Health in the fourth quarter worth $109,000. Finally, Corton Capital Inc. acquired a new stake in Hims & Hers Health in the third quarter valued at $122,000. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

See Also

Insider Buying and Selling by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.